Ascentage Pharma

日期: 2018-08-20
浏览次数: 42

Ascentage is a globally-focused, clinical-stage biopharma developing novel therapies for cancers, hepatitis B & age-related diseases. Its expertise is in developing inhibitors of protein-protein interactions (PPIs) to restore apoptosisor programmed cell death. There are seven drug candidates in Phase I or II clinical trials in the U.S., Australia and China, including a novel Bcl-2/Bcl-xL inhibitor as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs).

Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services